R&D News | pharmaphorum

News

Start-up Cradle tucks in $24m for protein engineering AI

Dutch-Swiss start-up Cradle has raised €22 million ($24 million) in first-round financing to develop its generative artificial intelligence (GenAI) and synthetic biology p

News

Shine rubs off Argenx after Vyvgart Hytrulo fails trial

Argenx has been riding high of late thanks to buoyant sales growth for its Vyvgart therapy for muscle-wasting disease generalised myasthenia gravis (gMG), but a failed pha

News

Boehringer puts IBM's GenAI into its antibody discovery tank

In another example of the pharma industry embracing generative artificial intelligence (GenAI), Boehringer Ingelheim will use technology developed by IBM to rev up antibod

News

Dupixent aces second COPD study, setting up FDA filing

With a second positive phase 3 trial in hand, Sanofi and Regeneron have said they plan to file for approval of Dupixent in chronic obstructive pulmonary disease (COPD), a

News

Is GSK’s Blenrep heading for a renaissance?

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the

News

Digital programme improves metabolic health in diabetes

A comprehensive digital approach to helping patients manage type 2 diabetes, combining continuous glucose monitoring (CGM) devices, wearables and a mobile app, has been sh

Start-up Cradle tucks in $24m for protein engineering AI

Shine rubs off Argenx after Vyvgart Hytrulo fails trial

Boehringer puts IBM's GenAI into its antibody discovery tank

Dupixent aces second COPD study, setting up FDA filing

Is GSK’s Blenrep heading for a renaissance?

Digital programme improves metabolic health in diabetes

Padcev/Keytruda scores again in early bladder cancer

How to meet your physicians where they are online

News

Editor's Picks